bd presentation 080409

8/8/2019 BD Presentation 080409

1/17


2/17

Corporate Presentation


3/17

Introduction

Pharmaceutical and Consumer Health Company

Headquarters in UK

Listed on the London Stock Exchange

Rapid Growth since 1991 both organic and through productacquisition

Products bought from leading global pharmaceutical

companies Sales and marketing presence in Europe, USA & India

Operational base in UK, USA & India


4/17

Introduction

Sales turnover 85 million year ended March 31, 2008

EBITDA of 17 million year ended March 31, 2008

Strong cash flow

More than 800 associates worldwide Wide range of products sold in more than 50 countries

Profitable, dividend paying company


5/17

CONSUMER HEALTH

Group Structure

Consumer HealthPharmaceuticals

Operational, Medical,

Regulatory and SharedServices

Management Board

Europe India Intl Europe India Intl USA

Group Board


6/17

Business Development PharmaceuticalsPresentation


7/17

Business Development: Business Model

PharmaceuticalBusinessDivision

Speciality Brands

Mature BrandsGenerics

Strategy focus


8/17

Our Pharmaceutical Business is split into 3 divisions:

Primary Care

Secondary Care

International

Geography

UK

Western Europe

International

Pharmaceutical Businesses


9/17

Extensive distributor base and distribution channels

Covers more than 50 countries:

Europe (including the New EU members)

Far east (excluding Japan and China)

Australia, New Zealand and ASEAN countries(Singapore, Malaysia etc)

Africa ( South Africa and selected countries)Established worldwide network of manufacturing partners(including API) built over 15 years

Distribution


10/17

Acquisition of niche tail end drugs mainly in Europeanmarkets to supplement the mature brand portfolio.

In-Licensing of niche specialty products to build brands.

Brand Leverage (reclassification)

Product Development (line extensions, New markets)

Diagnostics/Medical Devices

Alliances with multinationals to manage their non-coreproduct portfolio

Strategic Focus Business Development


11/17

Previous Acquisitions

1992- 1997

Acquisitions from Glaxo

Chloromycetin Ophthalmic Ointment and Redidrops from

Parke Davis & Co Pitressin and Amsidine from Parke Davis.

Rheumox from Wyeth

Stelazine from Smithkline Beecham

Transphase from Transdermal University of SouthCalifornia


12/17


1999

Kamillosan from Norgine

Lomotil from Monsanto

8 product licences ( including Fenbid and Stelazine) fromSmithKline

Nitrofurantoin from Procter & Gamble

2000

Trasidrex, Navispare, Navidrex from Novartis

Traxam from American Home Products


13/17


2001

Antigen Group of companies worldwide.

Diamox range of products for Europe from Wyeth Division

of American Home Products

2002

Cytostatics and other tail end (10) products from Wyeth


14/17

Products in late stages of development or technology

Medicines in disease areas which are not generallyfocused on by large multinational pharmaceuticals.

Palliative and critical care

Examples

Remodulin (treprostinil sodium) productAutodetect-Epidural device

In-Licensing


15/17

Goldshield has a team with knowledge and experience inthe following areas:

AcquisitionsIntegration of acquisitions

Developing and implementing growth strategies

In LicensingMarketing products

International Distributor management

Knowledge Strengths


16/17

Cardiology (Secondary Care)

Musculoskeletal and Joint diseases (Primary & Sec)

Pain/Anaesthesia (Secondary Care)

Therapeutic Focus


17/17

Pharmaceutical Products

more than 400 products worldwide

bd presentation 080409

Documents